This move is archived. Current quotes and coverage live on the stock page.
Follow MSCL
Satellos Bioscience Inc. faces a challenging trading day as its stock declines sharply.
Satellos Bioscience Inc. (MSCL.TO) is seeing a significant drop today, with shares down 3.62%. This decline comes as investors scrutinize the company’s recent decisions and the current market conditions.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$228.50M
52W high
$18.98
52W low
$7.56
1W change
-11.72%
Beta
1.15
Analyst Price Targets
Based on analyst covering MSCL · as of Sep 28, 2026
Wall Street analysts forecast MSCL stock price to rise 62.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.47
+62.2% Upside
Previously C$17.67 on Sep 17, 2026
Current Price
C$10.77
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
53.4%
Annualized
90-Day Vol
71.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$9.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.15 | C$8.44 – C$12.20 |
| 60 trading days | C$9.56 | C$7.37 – C$12.41 |
| 90 trading days | C$9.01 | C$6.55 – C$12.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should think about how Satellos' share consolidation might affect liquidity and how the market perceives the company.
Satellos Bioscience Inc. stock down 3.62% today
With a market cap of CA$291.84 million, this drop reflects investor uncertainty amid strategic corporate changes.
Bull case
Satellos is making progress in its research, especially in treating Duchenne muscular dystrophy. This focus could put the company in a strong position in the long run as clinical trials advance.
Bear case
The recent share consolidation, which aimed to qualify for a Nasdaq listing, might raise concerns about liquidity and investor confidence. This could be contributing to today’s stock decline.
Advertisement
Market Reaction to Share Consolidation
Satellos recently completed a 1-for-12 share consolidation to qualify for a potential Nasdaq listing. While this move is intended to boost its market presence, it has also sparked worries about reduced liquidity, which may have played a role in the stock's drop today.
Investor Sentiment and Future Outlook
The market's response to Satellos' recent announcements, including new board member appointments and clinical milestones, has been mixed. Investors are weighing the potential long-term benefits of its research against the immediate effects of the stock's performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
